Catalent scientist to lead webinar on mammalian cell line generation
(Research Triangle Park, N.C.) Gregory T. Bleck, PhD., Senior Director of Cell Line Engineering for Catalent Pharma Solutions, will lead a webinar on the characteristics of effective mammalian cell line generation process for bio-pharmaceutical production on May 25, 2010 at 2pm EDT. To register for this complimentary webinar please visit: https://www2.gotomeeting.com/register/853525658.
Dr. Bleck’s presentation will explore how steps in the generation of mammalian cell lines have been optimized to make the process more efficient. Dr. Bleck will also outline certain approaches to improve timelines and throughput. Additionally, data collected from Catalent’s development of more than 200 cell lines, each producing a different antibody or recombinant protein, will be reviewed. An outline of Catalent’s current CHO cell line development process that consistently yields clonal lines and upstream culture conditions that result in 2.5 – 5.0 g/L antibody production in five to six months will be presented.
Dr. Bleck received his BS and Ph.D. from the University of Wisconsin-Madison, and performed postdoctoral work at the University of Illinois-Urbana working in the areas of gene regulation and expression, and joined Catalent Pharma Solutions in 1998. At Catalent, he transferred his knowledge of gene expression and transgenic systems to the development and continued optimization of retrovector expression systems and is one of the developers of the GPEx® gene expression technology. The GPEx® process is used at Catalent to develop high producing mammalian cell lines to be used for bio-manufacturing at the Middleton, WI facility. Dr. Bleck has published more than fifty-five research papers and authored three book chapters. He has seven issued patents and eight patents currently under review.
For more information on Catalent’s broad range of biopharmaceutical development services, go to www.catalent.com/development.
Headquartered in Somerset, New Jersey, Catalent is one of the leading providers of advanced dose form and packaging technologies, and development, manufacturing, packaging and printing services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,000 at 30 facilities worldwide and in fiscal 2009 generated more than $1.6 billion of annual revenue. For more information, visit www.catalent.com.
